English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In an attempt to improve the performance of biologically active anticancer agents, a novel series of 1-substituent-4-(3,4-dimethoxyphenyl)-1 H -1,2,3-triazole hybrids  10–16  were designed and efficiently synthesized  via  the copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reactions of 4-ethynyl-1,2-dimethoxybenzene  1  with substituted-azides  2–8 . The structure of the new clicked 1,2,3-triazole hybrids  10–16  was confirmed on the basis of their elemental analysis and spectral data. Moreover, the cytotoxicity and  in vitro  anticancer activities of the newly synthesized compounds were also assessed against four different human cancer cell lines: Colon cancer (HCT116), Hepatocellular carcinoma (Hep G2), Breast cancer (MCF-7), and Lung carcinoma (A549). Among all the tested compounds, compound  15  revealed a higher potency against HCT116 compared to the activity of the reference drug, doxorubicin. This makes it an interesting candidate for further biological evaluation. Finally, a good correlation was obtained between the observed cytotoxicity evaluation of compound  15  against HCT116, from one side, and the molecular descriptors from another side.

Design and Click Synthesis of Novel 1- Substituted-4-(3,4-Dimethoxyphenyl)-1 H -1,2,3-Triazole Hybrids for Anticancer Evaluation and Molecular Docking